Weight-loss drug developer Metsera valued at $2.68 bln as shares jumped in market debut
Shares of weight-loss drug developer Metsera jumped nearly 42% in a strong Nasdaq debut on Friday, valuing the ARCH Venture ...
Half of Americans Support Weight-Loss Drugs Like Ozempic for Obesity, Poll
Cost is a major obstacle for many. The drugs can be expensive without insurance, with out-of-pocket expenses reaching ...
About Half of Americans Approve of Using Weight-Loss Drugs to Treat Obesity, AP-NORC Poll Finds
A new poll from The Associated Press-NORC Center for Public Affairs Research shows about half of U.S. adults believe it is a ...
The high cost of weight loss: How patients are fighting for access to breakthrough medications
CBS News Miami investigates the financial hurdles surrounding these medications and explores alternatives that may offer a ...
Americans split on using weight loss drugs to treat obesity: Survey
Americans are split on using weight loss drugs such as Ozempic and Wegovy to treat obesity or weight-related conditions, according to a new survey that was published on Friday. The new ...
How GLP-1 medications are transforming diabetes and weight loss treatment
Approximately 15.5 million Americans have been or currently are on injectable diabetes or weight-loss medications known as ...
Researchers Present Ozempic Alternatives—Without Sickening GI Side Effects
These compounds take a different approach to weight loss than existing medications, which can cause nausea, vomiting and ...
Weight-loss drug developer Metsera raises $275 million in US IPO
Weight-loss drug developer Metsera has raised $275 million after pricing its U.S. initial public offering at $18 per share, above its targeted range, the ARCH Venture Partners-backed biotech company ...
First for Women on MSN2h
Amycretin Shows Promising 22% Weight Loss in Trials-It May Rival Ozempic
Drug manufacturer Novo Nordisk's amycretin, an experimental weight-loss pill in clinical trials, may boast substantial weight ...